Oxurion enrolls patients to test its antibody PlGF in combinationwith Ranibizumab, to treat Diabetic Macular Edema

Belgian Oxurion has enrolled 70 patients for Phase 2 testing of its THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of Diabetic Macular Edema (DME).

Topline data from the study are expected by Q3 2019, the company said in a press release on Thursday.

The study will test 3 monthly intravitreal injections of THR-317 and ranibizumab in subjects with center-involved DME (CI-DME). The combination of ranibizumab and sham is used as control. Patients will be followed up until 3 months after the last injection.

Patrik De Haes, M.D., CEO of Oxurion nv, said: “We are delighted to announce the earlier than anticipated full enrollment of our Phase 2 study evaluating THR-317 in combination with ranibizumab for the treatment for DME. This proof of concept clinical study will for the first time provide important insights into the additional effect anti-PlGF (THR-317) could provide on top of anti-VEGF therapy, the current standard of care for treating DME patients.“